FDA grants priority review to Genentechs Tecentriq as firstline treatment of certain people with advanced NSCLC

FDA grants priority review to Genentech’s Tecentriq as first-line treatment of certain people with advanced NSCLC

The FDA is expected to make a decision on approval by June 19, 2020. “In the IMpower110 study, Tecentriq alone demonstrated a significant improvement in overall survival compared

More From BioPortfolio on "FDA grants priority review to Genentech’s Tecentriq as first-line treatment of certain people with advanced NSCLC"